Results from a randomized placebo-controlled clinical trial of a RBX2660-a microbiota-based drug for the prevention of recurrent Clostridium difficile infection
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Background: Despite advancements, recurrent Clostridium difficile infections (CDI) remain an urgent public health threat with insufficient response rates to currently approved antibiotic therapies. Microbiota-based treatments appear effective, but rigorous clinical trials are required to optimize dosing strategies and substantiate long-term safety. Methods: This randomized, double-blind, placebo-controlled phase 2B trial enrolled adults with 2 or more CDI recurrences to receive: 2 doses of RBX2660, a standardized microbiota-based drug (group A); 2doses of placebo (group B); or 1 dose of RBX2660 followed by 1 dose of placebo (group C). Efficacy was defined as prevention of recurrent CDI for 8 weeks following treatment. Participants who had a recurrence within 8 weeks were eligible to receive up to 2 open-label RBX2660 doses. The primary endpoint was efficacy for group A compared to group B. Secondary endpoints included the efficacy of group C compared to group B, combined efficacy in the blinded and open-label phases, and safety for 24 months. Results: The efficacy for groups A, B, and C were 61%, 45%, and 67%, respectively. The primary endpoint was not met (P = .152). One RBX2660 dose (group C) was superior to placebo (group B; P = .048), and the overall efficacy (including open-label response) for RBX2660-treated participants was 88.8%. Adverse events did not differ significantly among treatment groups. Conclusions: One, but not 2, doses of RBX2660 was superior to placebo in this randomized, placebo-controlled trial. These data provide important insights for a larger phase 3 trial and continued clinical development of RBX2660. Clinical Trials Registration: NCT02299570.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although the efficacy of retention enema had been once doubted, Orenstein and Dubberke et al. have proven it more efficient and safe than placebo in phase I and phase II recurrent CDI clinical trials.64,65”
From Fecal microbiota transplantation: Review and update (2019) · cites this paper as [65]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multistate point-prevalence survey of health care-associated infections
Magill, S. S., Edwards, J. R., Bamberg, W., Beldavs, Z. G., Dumyati, G., Kainer, M. A., Lynfield, R., Maloney, M., McAllister-Hollod, L., Nadle, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306801 · Cited by 3,931
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1085 · Cited by 2,690
Self-citationBurden of Clostridium difficile Infection in the United States
Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408913 · Cited by 2,641
Self-citationMicrobiota-mediated colonization resistance against intestinal pathogens
Buffie, C. G., & Pamer, E. G. (2013) · Nature reviews. Immunology · doi:10.1038/nri3535 · Cited by 1,564
Clostridium difficile— More Difficult Than Ever
Kelly, C. P., & LaMont, J. T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707500 · Cited by 1,313
Decreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010
Gough, E., Shaikh, H., & Manges, A. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir632 · Cited by 1,003
Kassam, Z., Lee, C. H., Yuan, Y., & Hunt, R. H. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.59 · Cited by 904
Self-citationBezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
Wilcox, M. H., Gerding, D. N., Poxton, I. R., Kelly, C., Nathan, R., Birch, T., Cornely, O. A., Rahav, G., Bouza, E., Lee, C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1602615 · Cited by 858
Self-citation
Cited by
Items 101–151 of 151
Diagnostic and therapy of severe Clostridioides difficile infections in the ICU
Guery, B. P., Barbut, F., & Tschudin‐Sutter, S. (2020) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000753 · Cited by 7
Dogra, S., Oneto, C., Sherman, A., Varughese, R., Yuen, A., Sherman, I., Cohen, A., Luo, Y., & Chen, L. A. (2022) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001778 · Cited by 7
Gîlcă-Blanariu, G.-E., Ștefănescu, G., Gîrleanu, I., Iqbal, T. H., Segal, J. P., Mullish, B. H., Quraishi, M. N., Keller, J. J., Molnár, T., Mégraud, F., et al. (2021) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-3297 · Cited by 6
Subramanian, C. R., Talluri, S., Khan, S. U., Katz, J., Georgetson, M. J., & Sinh, P. (2020) · Gastroenterology Research · doi:10.14740/gr1275 · Cited by 7
Kumari, M., & Kokkiligadda, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822909-5.00004-6 · Cited by 6
Khanna, S., Yoho, D. S., Handel, D. V., Clark, B. J., Awad, T., Guthmueller, B., Armandi, D., Knapple, W., Safdar, N., Baggott, B. B., et al. (2025) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848251396744 · Cited by 5
Self-citationGonzales-Luna, A. J., & Carlson, T. J. (2020) · Current Infectious Disease Reports · doi:10.1007/s11908-020-00729-8 · Cited by 5
Emerging alternatives against Clostridioides difficile infection
Romero-Rodríguez, A., de la Peña, C. M., Troncoso-Cotal, S., Guzmán, C., & Sánchez, S. (2022) · Anaerobe · doi:10.1016/j.anaerobe.2022.102638 · Cited by 5
Fecal Microbiota, Live-jslm (RBL; REBYOTA™) for Recurrent Clostridioides difficile Infection
Garcia, M. L., Castex, J., Duhaime, E., & Monk, M. (2024) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2024.105195 · Cited by 5
Tran, M.-C. N., Kullar, R., & Goldstein, E. J. C. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1581763 · Cited by 5
Klebsiella genus as driver of human disease: from infections to non-communicable disorders
Porcari, S., Ferrari, M., Melekhova, A., Severino, A., Fusco, W., Carlà, A. S., Maio, F. D., Tilg, H., Gasbarrini, A., Elinav, E., et al. (2026) · Nature Reviews Microbiology · doi:10.1038/s41579-026-01331-w · Cited by 4
Engineering live bacterial therapeutics to treat human diseases
Hwang, I. Y. (2023) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2023.100492 · Cited by 4
Javed, Q. U. A., Afzal, M., Ilyas, K., Sarfraz, A., & Sarfraz, Z. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.12.020 · Cited by 4
Advances in Clostridioides difficile therapeutics
Khanna, S. (2021) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1874919 · Cited by 4
Self-citationStrategies to prevent adverse outcomes following Clostridioides difficile infection in the elderly
Rauseo, A. M., Olsen, M. A. A., Reske, K. A., & Dubberke, E. R. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1717950 · Cited by 3
Self-citationOrenstein, R., Hecht, G. A., Harvey, A., Tillotson, G. S., & Khanna, S. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad456 · Cited by 3
Self-citationJain, S. R., Phoompoung, P., & Husain, S. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz376 · Cited by 3
McDonnell, K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14062040 · Cited by 2
Catella, C. M., Sarma, S., Hinesley, C. M., Febo, C. E., Breau, K. A., Durmusoglu, D., Purnell, E. F., Magness, S. T., Hall, C. K., Menegatti, S., et al. (2025) · Biotechnology and Bioengineering · doi:10.1002/bit.70102 · Cited by 2
Bahr, M. M. A., ElRakaiby, M. T., Madboli, A. E.-N. A., & Mansour, N. M. (2026) · Biologicals · doi:10.1016/j.biologicals.2026.101881 · Cited by 2
San-Juan, R., Origüen, J., Fernández‐Ruiz, M., Campion, K., Silva, J. T., López‐Medrano, F., Villa, J., Díaz‐Pollán, B., Callejas‐Díaz, A., Candela, G., et al. (2026) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlag032 · Cited by 2
Newer Therapeutics to Selectively Kill Clostridioides difficile and Restore the Microbiome
Granata, G., & Petrosillo, N. (2026) · Infectious Disease Reports · doi:10.3390/idr18020034 · Cited by 2
Obaid, N. A. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1374774 · Cited by 2
Juan, R. S., Origüen, J., Campion, K., Fernández‐Ruiz, M., Díaz‐Pollán, B., Callejas‐Díaz, A., Candela, G., Orellana, M. Á., Lora, D., Muñoz, I. L., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-072121 · Cited by 2
Cotto, C., Baker, K. A., Fallon, E., & Rimon, S. (2024) · Gastroenterology Nursing · doi:10.1097/sga.0000000000000847 · Cited by 2
Fecal Transplant Clinical Trials for Clostridioides Difficile : An Interview with Sahil Khanna
Khanna, S. (2020) · Future Microbiology · doi:10.2217/fmb-2020-0102 · Cited by 1
Self-citationLee, C., Feuerstadt, P., Louie, T., Bancke, L. L., Guthmueller, B., Harvey, A., Hoeyer, F., Orenstein, R., Dubberke, E. R., & Khanna, S. (2025) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848251395566 · Cited by 1
Self-citationChopra, T., Handel, D. V., Baggott, B. B., Orenstein, R., Reveles, K. R., Guthmueller, B., Srivastava, S., & Khanna, S. (2026) · Infectious Diseases and Therapy · doi:10.1007/s40121-026-01374-9 · Cited by 1
Self-citationMansoor, A., O’Neil, C. A., & Kwon, J. H. (2023) · Anaerobe · doi:10.1016/j.anaerobe.2023.102772 · Cited by 1
Hernanda, E. T., & Adawiyah, P. R. (2023) · Pubmedia Social Sciences and Humanities · doi:10.47134/pssh.v1i2.120 · Cited by 1
Bacterial Cocktail to Treat Clostridium difficile Infection: Primum Non Nocere
Million, M., Lagier, J., Chaudet, H., & Raoult, D. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy459 · Cited by 1
Vernon, J. J. (2019) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York) · Cited by 1
Κακαρούμπα, Ν. (2011) · Νημερτής · Cited by 1
Kwak, S., Choi, J., Hink, T., Reske, K. A., Blount, K., Jones, C., Bost, M. H., Sun, X., Burnham, C. D., Dubberke, E. R., et al. (2020) · doi:10.21203/rs.3.rs-17152/v1 · Cited by 1
Self-citationKerr, S. J. (2023) · Nottingham ePrints (University of Nottingham) · Cited by 1
Couturier, J. (2020) · theses.fr (ABES) · doi:10.70675/fe4590c9z9e1bz4fdez88fcz8e8c0a9023e4 · Cited by 1
Dubberke, E. R., Blount, K., & Gerding, D. N. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy460
Self-citationNormington, C. (2020) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Saha, S., Pardi, D. S., & Khanna, S. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.06.048
Self-citationFÖRÄLDER TILL EN ÄNGEL : Upplevelser av välbefinnande och lidande efter att barn avlidit i cancer
Gunnarsson, A. B., & Nylander, L. (2011) · DiVA (Linnaeus University)
Current insights into microbiome-based therapy. Review
Ткач, С. М., Dorofeyev, A. E., & Lm, R. (2024) · Modern Gastroenterology · doi:10.30978/mg-2024-1-73
Orenstein, R., Dubberke, E. R., Khanna, S., Lee, C., Yoho, D., Johnson, S., Hecht, G. A., Dupont, H. L., Gerding, D. N., Blount, K. F., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19351485
Self-citationLangdon, A. E., Schwartz, D. J., Bulow, C., Sun, X., Hink, T., Reske, K. A., Jones, C. R., Burnham, C.-A. D., Dubberke, E. R., & Dantas, G. (2021) · Figshare · doi:10.6084/m9.figshare.14052702
Self-citationLangdon, A. E., Schwartz, D. J., Bulow, C., Sun, X., Hink, T., Reske, K. A., Jones, C. R., Burnham, C.-A. D., Dubberke, E. R., & Dantas, G. (2021) · Figshare · doi:10.6084/m9.figshare.14052684
Self-citationSteczynska, J. P. (2023) · Nottingham ePrints (University of Nottingham)
AN OVERVIEW OF FAECAL MICROBIOTA TRANSPLANTATION
Gamde, S. M., OLUMESE, A. D., Iyeje, O. S., Tochukwu, F. E., & Biya, A. (2025) · Quantum Journal of Medical and Health Sciences · doi:10.55197/qjmhs.v4i5.181
Skinner, A. M., Lodise, T. P., Reilly, J., Guthmueller, B., Srivastava, S., & Axelrad, J. E. (2026) · Infectious Diseases and Therapy · doi:10.1007/s40121-026-01304-9
Santos, M. J. (2026) · Annals of Gastroenterology · doi:10.20524/aog.2026.1099
Novel options for the management of C. difficile : a look into the future
Granata, G., Petrosillo, N., & Taglietti, F. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2739273
Rebello, L., Chepyala, S., & Polineni, S. (2026) · Journal of Pharmacognosy and Phytochemistry · doi:10.22271/phyto.2026.v15.i5e.16171
Metadata
- Authors
- Dubberke, E. R., Lee, C. H., Orenstein, R., Khanna, S., Hecht, G., & Gerding, D. N.
- Affiliations
- Washington University in St. Louis (US)
- Island Health (CA)
- Mayo Clinic in Arizona (US)
- Mayo Clinic (US)
- Loyola University Medical Center (US)
- Edward Hines, Jr. VA Hospital (US)
- Corresponding author
- Dubberke, Erik R
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-03-29
- Volume
- 67
- Issue
- 8
- Pages
- 1198-1204
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2795021885
- Cited by
- 140
- References
- 37
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 21 · 2023: 20 · 2022: 19 · 2021: 18 · 2020: 21 · 2019: 16 · 2018: 4
- FWCI
- 11.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Rebiotix Inc.
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- RBX2660, recurrent Clostridium difficile infection, microbiota-based therapy, fecal microbiota transplantation, dosing regimen, treatment efficacy, drug safety, adverse events
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents, Biological Therapy, Clostridium Infections, Diarrhea, Double-Blind Method, Enterocolitis, Pseudomembranous, Feces, Female, Humans, Male, Middle Aged, Recurrence, Clostridioides difficile, Treatment Outcome, Young Adult, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.